Top Page
Rubicon Organics
(OTC:ROMJ)
Rubicon Organics (ROMJ) vs. iShares MSCI Canada ETF (EWC)
Rubicon Organics Business Overview & Revenue Model
Rubicon Organics Earnings Call Summary
Rubicon Organics Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 48.70M | 40.12M | 35.52M | 22.61M | 9.39M |
| Gross Profit | 15.42M | 13.14M | 13.81M | 1.51M | -663.96K |
| EBITDA | 1.86M | 1.95M | 217.00K | -10.87M | -10.37M |
| Net Income | -2.56M | -1.82M | -3.86M | -14.52M | -14.98M |
Balance Sheet | |||||
| Total Assets | 56.61M | 54.89M | 56.11M | 54.84M | 51.07M |
| Cash, Cash Equivalents and Short-Term Investments | 9.86M | 10.91M | 8.29M | 11.58M | 12.14M |
| Total Debt | 9.89M | 10.40M | 10.22M | 9.82M | 13.99M |
| Total Liabilities | 19.21M | 17.00M | 17.77M | 15.94M | 22.23M |
| Stockholders Equity | 37.40M | 37.89M | 38.33M | 38.90M | 28.84M |
Cash Flow | |||||
| Free Cash Flow | 1.85M | 2.47M | -2.50M | -15.94M | -20.30M |
| Operating Cash Flow | 3.40M | 5.05M | 1.95M | -10.44M | -14.31M |
| Investing Cash Flow | -1.55M | -2.73M | -4.45M | -5.50M | 3.08M |
| Financing Cash Flow | -1.77M | -804.01K | -838.56K | 15.30M | 21.26M |
Rubicon Organics Technical Analysis
Rubicon Organics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $54.79M | 4.04 | 20.78% | ― | -15.44% | ― | |
65 Neutral | C$45.80M | ― | -24.12% | ― | 18.82% | -9328.57% | |
56 Neutral | C$28.55M | ― | -2.68% | ― | 29.78% | 68.83% | |
56 Neutral | $30.64M | ― | -12.58% | ― | 9.90% | -24.19% | |
50 Neutral | $31.32M | ― | -203.40% | ― | 14.82% | 64.51% | |
46 Neutral | C$201.68M | -3.28 | -23.14% | 1.87% | 20.75% | -0.36% | |
44 Neutral | C$32.99M | ― | -18.73% | ― | 44.21% | 21.93% |
Rubicon Organics Corporate Events
Rubicon Organics has announced its Annual General and Special Meeting to be held on July 31, 2025, in Vancouver. The meeting will cover several key agenda items, including the election of directors, appointment of auditors, and approval of an amendment to the company’s Omnibus Equity Incentive Plan. This meeting is significant for stakeholders as it addresses governance and strategic decisions that could impact the company’s future operations and market positioning.
The most recent analyst rating on (TSE:ROMJ) stock is a Buy with a C$1.10 price target. To see the full list of analyst forecasts on Rubicon Organics stock, see the TSE:ROMJ Stock Forecast page.
Rubicon Organics has launched its new 1964 Supply Co.™ All-in-One Full Spectrum Extract Resin Vapes in Canada, expanding its premium cannabis product offerings. This launch marks a strategic step in Rubicon’s growth plan, aiming to attract consumers from the legacy market by offering high-quality, full-spectrum products at competitive prices, setting a new standard in a segment dominated by distillate-based products.
The most recent analyst rating on (TSE:ROMJ) stock is a Buy with a C$1.10 price target. To see the full list of analyst forecasts on Rubicon Organics stock, see the TSE:ROMJ Stock Forecast page.
Rubicon Organics has acquired a 47,500 sq. ft. indoor cultivation facility in Hope, British Columbia, marking a significant step in its strategy to expand premium cannabis production. This acquisition is expected to increase the company’s production capacity by over 40%, supporting its growth in both domestic and international markets. The facility is anticipated to reach full production capacity by the end of 2026, with revenue contributions expected in the first half of 2026. This move strengthens Rubicon’s leadership in the premium cannabis segment and aligns with its focus on innovation and international expansion.
The most recent analyst rating on (TSE:ROMJ) stock is a Buy with a C$1.10 price target. To see the full list of analyst forecasts on Rubicon Organics stock, see the TSE:ROMJ Stock Forecast page.
Rubicon Organics reported a strong Q1 2025 with a 39.2% increase in net revenue to $12.4 million and a positive Adjusted EBITDA of $0.7 million. The company removed conditions for the acquisition of the Hope Facility, which will expand production capacity by 40%, and completed a $4.5 million private placement to support future growth. With a national market share in various cannabis categories and international certification, Rubicon is well-positioned for long-term growth and expansion in both domestic and export markets.
The most recent analyst rating on (TSE:ROMJ) stock is a Buy with a C$1.10 price target. To see the full list of analyst forecasts on Rubicon Organics stock, see the TSE:ROMJ Stock Forecast page.
Rubicon Organics has cleared all conditions for acquiring the Hope Facility, a 47,500 square foot indoor cultivation site in Hope, British Columbia, from Medipharm Labs Inc. This acquisition is expected to significantly enhance Rubicon Organics’ production capacity, enabling the company to meet increasing demand for its premium cannabis products and support its growth strategy. The company anticipates closing the acquisition in the second quarter and expects the first harvests by the end of 2025, with revenue realization in early 2026. This strategic move is seen as pivotal for Rubicon Organics in accelerating innovation and driving long-term shareholder value.
The most recent analyst rating on (TSE:ROMJ) stock is a Buy with a C$1.10 price target. To see the full list of analyst forecasts on Rubicon Organics stock, see the TSE:ROMJ Stock Forecast page.
Rubicon Organics Inc. announced it will release its Q1 2025 financial results on May 27, 2025, followed by a conference call on May 28, 2025. This announcement is part of Rubicon’s strategy to maintain transparency with stakeholders and highlights its commitment to achieving industry-leading profitability through its premium cannabis offerings.
The most recent analyst rating on (TSE:ROMJ) stock is a Buy with a C$1.10 price target. To see the full list of analyst forecasts on Rubicon Organics stock, see the TSE:ROMJ Stock Forecast page.
Rubicon Organics has appointed Glen Ibbott as its Interim CFO, following the departure of Janis Risbin from her full-time role. Ibbott, a seasoned financial executive with extensive experience in the cannabis industry, previously served as CFO at Aurora Cannabis, where he contributed to the company’s rapid growth and international expansion. His appointment comes at a strategic time for Rubicon Organics as it scales new capacity and explores new markets for its premium cannabis brands. The company is also initiating a search for a permanent CFO, emphasizing the need for a leader with deep financial expertise and a strong understanding of the cannabis industry.
The most recent analyst rating on (TSE:ROMJ) stock is a Buy with a C$1.10 price target. To see the full list of analyst forecasts on Rubicon Organics stock, see the TSE:ROMJ Stock Forecast page.
Rubicon Organics Inc. has successfully closed a non-brokered private placement offering, raising approximately $4.5 million. The proceeds will be used for the start-up and acquisition costs of a new facility in Hope, B.C., as well as for pre-roll automation, other capital investments, and general working capital. The participation of the company’s Board of Directors in the offering is considered a related party transaction but falls within regulatory exemptions. This move is expected to strengthen Rubicon’s operational capabilities and market positioning.
Rubicon Organics Inc. has announced an increase in its non-brokered private placement offering from $3,000,000 to $4,500,000 due to strong market demand. The additional capital will be used for the start-up and acquisition costs of a new facility in Hope, BC, as well as pre-roll automation and other capital investments, aiming to accelerate the company’s growth initiatives and strengthen its position in the Canadian premium cannabis market.